Immunosuppressant target proteins
AssigneeARIAD Pharmaceuticals, Inc.
InventorsVivian Berlin, Maria Isabel Chiu, Guillaume Cottarel, Veronique Damagnez
Life of this patent
Estimating the term…
Abstract
The present invention relates to the discovery of novel proteins of mammalian origin which are immediate downstream targets for FKBP/rapamycin complexes.
Claims22
A nucleic acid encoding a fusion polypeptide consisting of:
- a portion of a RAPT1 protein of 200 amino acid residues or less, which RAPT1 portion (a) is encoded by a nucleic acid which hybridizes to one of SEQ ID NOs. 1, 11, 13, 15 or 17 under stringent conditions including a wash step of 0.2.times. SSC at 65.degree. C., and (b) binds an FKBP/rapamycin complex in a rapamycin dependent manner;
- and one or more additional polypeptide portions heterologous to a native RAPT1 protein.
A nucleic acid encoding a fusion polypeptide consisting of 50-133 residues from residues 1272-1404 of SEQ ID NO. 12, or a mutant thereof having from 1 to 7 amino acid differences with SEQ ID NO. 12;
- and one or more amino acid sequences heterologous thereto.
A nucleic acid encoding a fusion polypeptide consisting of residues 1272-1404 of SEQ ID NO. 12;
- and one or more optional amino acid sequences which are heterologous thereto.
A nucleic acid encoding a fusion polypeptide consisting essentially of:
- a portion of a RAPT1 protein of 200 amino acid residues or less, which RAPT1 portion (a) is encoded by a nucleic acid which hybridizes to SEQ ID NO. 1, 11 or 13 under stringent conditions including a wash step of 0.2.times. SSC at 65.degree. C., and (b) binds an FKBP/rapamycin complex in a rapamycin dependent manner;
- wherein the RAPT1 portion does not include an endogenous kinase activity;
- and one or more additional polypeptide portions heterologous to a native RAPT1 protein.
Dependencies are inferred from the claim text.